Oncolytic Virotherapy for Hematological Malignancies by Bais, Swarna et al.
Hindawi Publishing Corporation
Advances in Virology
Volume 2012, Article ID 186512, 8 pages
doi:10.1155/2012/186512
Review Article
OncolyticVirotherapy for Hematological Malignancies
Swarna Bais,1 EricBartee,2 Masmudur M. Rahman,2
Grant McFadden,2 and Christopher R. Cogle1
1Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, ARB R4-202,
P.O. Box 100278, Gainesville, FL 32610-0278, USA
2Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, ARB R4-295, P.O. Box 100266,
Gainesville, FL 32610, USA
Correspondence should be addressed to Grant McFadden, grantmcf@uﬂ.edu and Christopher R. Cogle, c@uﬂ.edu
Received 6 July 2011; Accepted 31 August 2011
Academic Editor: Nanhai G. Chen
Copyright © 2012 Swarna Bais et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes
(MDSs) primarily aﬀect adults and are diﬃcult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can
be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer cells remains
a major challenge. Ex vivo manipulations of the autograft to purge cancer cells using chemotherapies and toxins have been
attempted. Because these past strategies lack speciﬁcity for malignant cells and often impair the normal hematopoietic stem and
progenitor cells, prior eﬀorts to ex vivo purge autografts have resulted in prolonged cytopenias and graft failure. The ideal ex vivo
purging agent would selectively target the contaminating cancer cells while spare normal stem and progenitor cells and would be
applied quickly without toxicities to the recipient. One agent which meets these criteria is oncolytic viruses. This paper details
experimental progress with reovirus, myxoma virus, measles virus, vesicular stomatitis virus, coxsackievirus, and vaccinia virus as
well as requirements for translation of these results to the clinic.
1.HematologicalMalignancies
Hematological malignancies include leukemias, lymphomas,
multiple myeloma (MM), and the myelodysplastic syn-
dromes (MDSs) that most often aﬀect individuals older than
60 years of age. These blood cancers aﬀect approximately
10% of Americans diagnosed with cancer each year, and an
estimated 140,000 were newly diagnosed in 2010 (National
Cancer Institute, Surveillance Epidemiology, and End Re-
sults).Unfortunately,despite bestavailabletherapies,anesti-
mated 50,000 individuals died from these diseases in 2010.
The causes of hematological cancers vary depending
on the speciﬁc malignancy. Exposure to environmental
toxins such as benzenes, prior cytotoxic treatment such as
radiotherapy or chemotherapy for an antecedent cancer, as
wellasinfectionshaveallbeenimplicatedascausativefactors
in initiating hematological malignancies. In contrast, recur-
rent cytogenetic abnormalities have also been observed in
hematological malignancies. These abnormalities often form
the basis for assigning prognosis. For example, in acute
myeloid leukemia (AML), recurrent mutations that portend
forahighriskofrelapseafterconventionaltreatmentinclude
those with chromosome 7 abnormalities, chromosome 5
abnormalities,complexkaryotypicabnormalities,andmuta-
tions in the FLT3 gene. Genetic information can also indicate
the most appropriate therapy. For instance, in patients with
acute promyelocytic leukemia with the abnormal PML-
RARA gene fusion, treatment with all transretinoic acid
(ATRA)andcytotoxicchemotherapycancureapproximately
90% of patients [1]. In patients with MDS and deletion of
chromosome 5q, treatment with lenalidomide can improve
blood counts in 75% of patients [2].
Based on the utility of genetic information in deter-
mining prognosis and type of treatment in hematological
malignancies, increased attention has been given to fully
assessing the blood cancer genome. Recently, whole genome
sequencing of an AML patient’s DNA revealed several novel
mutations never before associated with oncogenesis [3].
This technology also recently led to the discovery of TET22 Advances in Virology
mutations as common gene mutations in MDS and empha-
sized the importance of epigenetic dysregulation in this
disease [4, 5]. Because of the abnormal DNA methylation
that occurs after TET2 mutations, ﬁnding this mutation
in an MDS patient’s genome may indicate treatment with
a hypomethylating agent such as azacitidine or decitabine
[6]. Recently, whole genome sequencing was reported useful
in determining the best treatment for a patient with AML
[7]. Thus, genome analysis has the strong potential for
personalized medicine in hematological malignancies.
In some hematological malignancies, such as MDS, ab-
normalities in bone marrow stromal cells are believed to
aﬀect hematopoietic stem and progenitor cells, leading to
neoplastic transformation [8]. Evidence that the bone mar-
row microenvironment is an important factor in the oncoge-
nesis of hematological malignancies has spurred great inter-
estinregulatingmicroenvironmentalinteractionsasameans
for improved therapies. We have targeted blood vessels in the
leukemia niche with the novel vascular disrupting combre-
tastatin,OXi4503,andhavesuccessfullyregresseddisease[9].
This work has been translated into a phase I clinical study
(http://www.ClinicalTrials.gov Identiﬁer NCT01085656).
Cancer stem cells have been identiﬁed for some hema-
tological malignancies [10]. In the speciﬁc case of acute
myeloid leukemia (AML), a small subpopulation of cancer
stem cells have been identiﬁed in the CD34+CD38−CD123+
fraction [11, 12]. In MM, myeloma stem cells have been
found in the CD138− B cell fraction, which replicate and
diﬀerentiate into CD138+ malignant plasma cells [13]. In
chronic myeloid leukemia (CML), hematopoietic progenitor
cells are believed to be the cancer-initiating cells which are
endowed with cancer stem cell properties after acquiring the
abnormal BCR/ABL gene fusion [14]
2.Treatment of Hematological Malignancies
The cornerstone of conventional therapy for hematolog-
ical malignancies includes agents that block cell division
such as antimetabolites (e.g., cytarabine), DNA alkylating
agents (e.g., cyclophosphamide), and anthracyclines (e.g.,
daunorubicin). Treatment with these agents induces initial
remission in a high percentage of patients; however, relapsed
disease remains a major challenge in treating patients with
hematological malignancies.
For example, in cases of AML, remission rates with
standard induction chemotherapy such as seven days of con-
tinuously infused cytarabine and three days of anthracycline
bringaboutinitialcompleteremissionsinapproximately30–
70%ofpatients.However,inolderindividuals,whoaremore
commonly diagnosed with AML, long-term prognosis can
be grim with only 10–20% of patients surviving without
disease [15]. For patients with high risk AML, allogeneic
HCT is used and can be curative in approximately 40% of
patients. With this procedure, the donor immune system
recognizes any residual leukemia in the recipient as foreign
because of minor human leukocyte antigen mismatches
and/or unique AML antigens, resulting in elimination and
persistent surveillance for the malignant cells. By similar
mechanisms, the donor immune system can recognize the
recipient’s normal organs (skin, gastrointestinal tract, liver,
lungs, joints) as foreign and elicit graft versus host disease
(GVHD). Although potentially curative, most AML patients
due to their age-related comorbidities are not ﬁt for the
high risks associated with allogeneic HCT (e.g., GVHD, life-
threatening infections, organ toxicity) and/or do not have
a suitable allogeneic stem cell donor. Experimental therapies
for AML have recently included speciﬁc mutation-targeting
agents such as FLT3 inhibitors for patients with internal
tandem duplications in the FLT3 gene of the AML clone.
However, results from these clinical trials have been disap-
pointing.
For patients with MM, treatment decisions are often
based on risk for refractory and relapsed disease. Certain
chromosomeabnormalities,suchasdeletionofchromosome
13, portend for poor prognosis. In addition, gene expression
proﬁling can be used to risk-stratify MM disease [16]. For
patients with standard risk MM, initial treatment is depen-
dent on the patient’s eligibility for high-dose chemotherapy
followed by autologous HCT, which can prolong disease-
free and overall survival but carries treatment-related risks
of organ toxicity, need for transfusions, and life-threatening
infection. Patients eligible for autologous HCT are treated
withnonalkylatingagentinductiontherapiessuchasthalido-
mide and dexamethasone or lenalidomide and dexametha-
sone [17, 18]. After this initial therapy, patients have the
option of early versus delayed autologous HCT. If early HCT
isused,thenasecondHCTcanbeperformedinpatientswho
do not achieve a very good partial remission or better [19].
If the patient elects for delayed high-dose chemotherapy fol-
lowed by autologous HCT, then transplant is not performed
until initial induction therapy brings about a plateau in
response or progressed disease develops. Even using these
treatments, however, autologous HCT rarely brings about
cures for MM, as the disease nearly always relapses.
3. Autograft Contamination and Disease
Relapse after Transplant
Despite the signiﬁcant increase in use of autologous HCT
for hematologic malignancies, disease relapse is a primary
cause of death after transplant. Graft contamination is
thought to be the chief reason for posttransplant relapse.
Thispremiseissupportedbymultiplelinesofevidence.First,
transplant of HSPC from syngeneic (identical twin) donors
leads to lower incidences of disease relapse in patients with
multiple myeloma, low-grade non-Hodgkin’s lymphoma,
AML, and ALL [20–22]. Second, numerous reports show
that transplanted autografts contain minimal residual dis-
ease (MRD) in a variety of patients with cancer [23–39].
The level of MRD, detected by ﬂow cytometry, immuno-
histochemistry, and molecular methods, directly correlated
with risk of disease relapse and death. Whereas these lines
of evidence show a strong correlation, direct proof of
contaminated autografts through tracing studies are most
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marking studies [40–42]. In these clinical studies, autolo-
gous HSPCs were genetically tagged and then transplanted.
Relapsed disease was evaluated for the tag. In a variety of
leukemias and cancers, the posttransplant relapsed disease
contained the pretransplant tag. Together, these lines of
evidencesupportthepremisethatcontaminatingcellswithin
the autologous transplant graft can be the origin of relapsed
disease after transplant.
4.PurgingStrategies
Considering the high rates of refractory and relapsed in
patients with hematological malignancies and evidence of
contaminating cancer cells in autologous HCT grafts, it
is possible that graft purging of contaminating cells may
improveposttransplantdisease-freeandoverallsurvival.Ide-
ally, a safe and eﬀective purging strategy should speciﬁcally
target the contaminating malignant clone and spare normal
HSPC needed for reconstitution of immunity, erythropoieis,
and platelets.
Several purging strategies have been attempted to selec-
tively target malignant cells from autologous HCT grafts.
One strategy is to treat the autologous graft after collection
but prior to transplant back into the patient. A number of
these ex vivo purging techniques have been tested such as:
(i) chemotherapy with antiproliferative drugs such ma-
fosfamide and 4-hydroperoxycyclophosphamide (4-
HC,activemetaboliteofcyclophosphamide)[43,44];
(ii) CD34+ stem/progenitor cell enrichment using im-
munomagnetic selection [45];
(iii) immunotoxins or hybrid cytotoxic proteins designed
toselectivelykillcancercellssuchasheregulin(HRG)
Pseudomonas exotoxin (PE) 40 [46];
(iv) immunomagnetic removal of tumor cells when the
tumor cells express a unique antigen [47];
(v) monoclonal antibodies such as alemtuzumab (anti-
CD52) and rituximab (anti-CD20) [48];
(vi) photodynamic purging by rhodamine [49].
Unfortunately most of these ex vivo purging techniques
also impaired normal hematopoietic stem and progenitor
(HSPC)functionandthereforehavenottranslatedtoroutine
clinical practice for autologous HCT [50]. Purging strategies
utilizing cytotoxic chemotherapy can be nonselective to
cancer cells, and HSPC can be susceptible to the cytotoxic
drugs [43, 44]. Immunomagnetic selection based on one
cell surface marker (i.e., CD34) can enrich for normal
HSPC; however, this selection process is never 100%, and the
positive fraction may contain contaminating cancer cells
[45, 47]. Moreover, discriminating normal from malignant
HSPC can be diﬃcult when using just cell surface markers
becausethetwopopulationsaresometimesindistinguishable
by immunophenotyping. Given similarities in immunophe-
notype, immunotoxins may target both malignant and
normal HSPC, leading to impaired normal hematopoiesis
and posttransplant hematopoietic reconstitution [46, 48].
Ideally, ex vivo purging is selective for the cancer cells yet
spares normal HSPC. Moreover, the ideal purging technique
should be applied quickly (within minutes-to-hours) so that
the transplant process is not delayed and any modiﬁcations
to standard transplantation protocols are minimized. Cell
viability is a time-dependent variable, and the quicker the
manipulation the higher cell viability for transplant. In the
postthaw setting, cell viability can diminish within hours,
thus purging techniques applied to thawed products should
be especially time sensitive in order to provide patients with
the highest cell viability for transplant.
5. Oncolytic Virotherapy for
Hematological Malignancies
Oncolytic viruses may meet criteria as ideal purging
agents for hematological malignancies. Speciﬁcally, certain
oncolytic viruses selectively target malignant hematopoietic
cellssuchasmultiplemyelomaandleukemiacellswhilespar-
ing normal HSPCs [51]. This capacity to purge autologous
HCT grafts makes oncolytic viruses particular attractive for
potential use in the clinical transplant setting (Figure 1). A
few oncolytic viruses have already been translated into the
clinic (Table 1).
One potential purging agent is coxsackievirus A21
(CVA21) based on its ability to selectively target hemato-
logical malignant cells [52]. CVA21, a common enterovirus,
exhibited a potent cytostatic and cytocidal eﬀect against
three MM cell lines with reduced cytotoxicity against normal
human peripheral blood mononuclear cells (PBMCs) [53].
CVA21 speciﬁcity is believed to be related to expression
of intercellular adhesion molecule-1 (ICAM-1) and decay
accelerating factor (DAF) on the surface of target cells. While
the immunocompromised status of MM patients receiving
chemotherapy poses a concern for the use of virotherapy, it
may be in these patients that CVA21 virotherapy will have
the most successful outcome due to the lack of antiviral
immunity. Disseminated CVA21 infection can be con-
trolled by antiviral compounds, such as pleconaril [54]o r
immunoglobulin[55].CVA21hasalreadybeenadministered
to end-stage melanoma patients without adverse eﬀects [56],
and further human trials are currently underway to evaluate
safety.
Another potential oncolytic virus for the treatment of
hematological malignancies is reovirus [57]. Reovirus is a
double-stranded RNA virus that is replication competent
and preferentially infects cells with hyperactivated signaling,
for example, in the Ras pathway. When reovirus was used
to ex vivo purge MM cells from admixtures of apheresis
products, purging was incomplete: only 50% of the MM cells
were eﬀectively purged. Also, reovirus was unable to purge
follicular lymphoma and Burkitt’s lymphoma cells [58]. A
major advantage with reovirus is that it does not aﬀect nor-
malHSPCs.Therefore,reovirusmayhavepotentialincertain
hematological malignancies, but it remains to be deﬁned
how clinically eﬀective the virus is at eliminating each type
of cancer.4 Advances in Virology
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Figure 1: Proposed treatment schema of oncolytic virotherapy for patients with hematological malignancies undergoing high-dose
chemotherapy and autologous HCT.
Vesicular stomatitis virus (VSV) is another virus with
oncolytic potential [59]. This negative strand RNA virus
lacks toxicity for HSPCs in culture and has oncolytic activity
against AML cell lines. Moreover, VSV can purge MM from
mobilized PBSC CD34+ cells [60].
The Edmonston-B vaccine strain of measles virus (MV-
Edm) also has reported oncolytic activity against MM. Using
sixclinicalMMsamplesandatransplantmodelintoimmun-
odeﬁcient mice, this measles virus successfully purged
myelomacells[61].Theintrinsictumorselectivecytotoxicity
is an attractive feature of this agent. They also noted that
administration of MV-Edm into MV-susceptible transgenic
mice expressing the human CD46 receptor resulted in infec-
tion of macrophages in spleen, lymph nodes, and peritoneal
cavity [62]. To enhance virus speciﬁcity, they generated an
anti-CD38 scFv and demonstrated that display of scFv redi-
rected virus binding and entry into CD38 receptor positive
cells that were devoid of natural measles receptors [63].
The MV-Edm virus is currently in a phase I clinical study
for recurrent or refractory MM where it is administered
systemically via intravenous route along with cyclophos-
phamide chemotherapy (http://www.ClinicalTrials.gov ID
NCT00450814) [64]. In this trial, the investigators are
using the MV-NIS Edmonston lineage which was genetically
engineered to express the human sodium iodide symporter
(NIS). Insertion of the NIS protein into MV enables phar-
macokinetic monitoring of the virus by means of radioactive
iodine(123I)administration.CellsinfectedwithMV-NISwill
show increased uptake of the radioactive iodine, and this
uptake can be serially tracked in real time. The patient’s
Table 1: Oncolytic viruses for the treatment of hematological
malignancies.
Virus Disease targets Clinical studies References
Reovirus MM, NHL, CLL In development [57]
Myxoma virus AML, MM In development [51]
Measles virus MM Ongoing
(NCT00450814)
[64]
Vaccinia virus MM Case report [76]
MM: multiple myeloma; NHL: non-Hodgkin’s lymphoma; CLL: chronic
lymphocytic leukemia; AML: acute myeloid leukemia.
normal thyroid function is protected by coadministration of
a normal thyroid hormone, triiodothyronine (T3).
Live attenuated measles virus (MV) has potent oncolytic
activity against MM tumor xenografts. The virus is tumor
selective and preferentially targets cells that express high
levels of CD46 receptors [65]. A vaccine strain of MV causes
regression of large established human lymphoma xenografts
in immunodeﬁcient mice. MV is a negative-strand RNA
virus, and, interestingly, the presence of anti-MV antibodies
does not compromise the oncolytic eﬀect of MV [66].
Adachi et al. reported a midkine promoter based con-
ditionally replicative adenovirus (Ad) for the treatment of
pediatric solid tumors and bone marrow tumor purging. A
conditionally replicative Ad in which the expression of E1 is
controlled by the MK promoter achieved high levels of viral
replication in neuroblastoma or Ewing’s sarcoma cells and
induced tumor cell killing. No damage to CD34+ cells wasAdvances in Virology 5
seen, even after three hours of infection at 1000 MOI [67].
Adenovirus serotype 5 (Ad5) and other low-seroprevalence
adenoviruses may have utility as oncolytic agents against
MM and other hematological malignancies [68].
Tumor-speciﬁc double-deleted Vaccinia virus has also
been tested in multiple myeloma [69]. Esfandyari et al. were
the ﬁrst to document permissiveness of lymphoma cells to
oncolytic herpes viruses and introduced ELK as a suitable
factor for predicting tumor susceptibility to novel anticancer
agents [70].
Oncolytic rat parvovirus, H-1PV, may be a potential
candidate for the treatment of some non-Hodgkin’s B-cell
lymphomas, including those resistant to apoptosis induction
byrituximab.H-1PVeﬃcientlykilledthroughnecrosiswhile
sparing normal B lymphocytes [71].
Recently, we showed that myxoma virus (MYXV) has the
capacity to selectively target primary human leukemia cells
while spare normal HSPCs [51]. Poxviruses such as MYXV
can bind and initiate entry into most mammalian cells but
then discriminates permissive versus nonpermissive cells by
virtue of the cell signaling circuitry of the infected cell. We
have shown that upregulated AKT signaling, either as con-
stitutive phosphorylation or induced by virus infection [72],
regulates MYXV permissiveness in a wide variety of human
solid tumor cell lines [73]. Considering the complexity and
heterogeneity of cancer cells, this pathway is likely not the
only mechanism for cancer cell speciﬁcity and there may
be other mechanisms to explain the virus’ discrimination
between leukemia cells and normal HSPC. For example,
when normal macrophages are infected with MYXV, the cells
rapidly coinduce two antiviral cytokines (tumor necrosis
factor and type I interferon) by a RIG-I-dependent signaling
mechanism, which then aborts MYXV infection in normal
somatic cells in a paracrine-like manner [74]. Thus, it could
be that normal HSPCs are competent for this synergy,
whereasmalignantHSPCs,suchasAMLcells,aredefectivein
some aspect of the tumor necrosis factor/interferon pathway.
The mechanism for selective killing of cancer is still being
studied, but two important factors include (1) most human
cancer cells lack type I IFN and TNF synergy responses [75]
and (2) most cancer cells have excessive levels of activated
Akt, which facilitates MYXV replication [73].
6.ClinicalTranslationof Oncolytic Virusesas
Purging Agents for HCT
For successful clinical translation, there are some unique
requirements for oncolytic virotherapy in the setting of
purging cancer cells prior to HCT. First, the OV must spare
normal HSPCs. Second, the purging strategy should be sim-
ple and quick, especially when using cryopreserved stem cell
products. After thawing autologous cryopreserved HSPC,
cell viability decreases quickly (within minutes to an hour);
thus any postthaw intervention must be quickly performed
to ensure transplant of an adequate number of viable HSPC.
Finally, the oncolytic virus must show limited to no infection
of recipient somatic cells or tissues considering that all
transplant recipients are highly immunocompromised after
high-dose chemotherapy and autologous HCT.
In addition to showing preclinical safety and eﬃcacy,
the translation of oncolytic virotherapy for hematological
malignancieswillalsorequiretheabilitytomassivelyscaleup
manufacture of clinical grade virus under good manufactur-
ing process (GMP) conditions. This process will necessitate
facilities with expertise in virus production.
Currently, there are no clinical studies of oncolytic
viruses as purging agents prior to autologous HCT. However,
if a virus system can be optimized to meet minimum clinical
criteria,thenoncolyticvirotherapywouldhavemajorimpact
inhowwetreatpatientswithbloodcancers.Already,promis-
ing experimental progress indicates that early phase clinical
studies of oncolytic viruses as purging agents for HCT are
imminently approaching.
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